Search

Introduction: Robotics is concerned with the connection of perception to action; in this to each other but serve very different purposes.AI is a branch of computer science which involves developing computer programs to complete tasks that would otherwise require human intelligence. To assess the knowledge and attitude of dentists the role of robotics (R) and artificial intelligence (AI) in oral health and preventive dentistry. Materials And Methods: A cross-sectional study in which data was collected from dentist population. A total of 600 participants answered 15 closed-ended questions. The questionnaire's validity and reliability were evaluated for vetting and remarks. The questionnaire collected demographic data of participants and their knowledge and attitude about Robotics and Artificial intelligence. Descriptive statistical analysis was performed using chi-squared testwith statistical significance set at p < 0.05. Results: The majority of the participants (n = 600; 57.5%/42.5%) were males and females. Dental students, dentist school graduates/ interns, and postgraduate dentists comprised of 56.6%, 23.3%%, and 20% respectively. Most of the respondents gave affirmative answers for knowledge and attitude of R and AI (56.6%,and 75%).These were significantly above the overall affirmative answers, as the corresponding point lies above 95% UCL (upper confidence limit). Conclusion: Most dentists were unacquainted with R and AI. Dentists had a positive attitude towards R/AI, but due to inadequate knowledge and understanding, its use and applications were very limited. There is significant need in the near future to increase awareness of this concept, as it may increase treatment efficiency and effectiveness

Ewing’s sarcomas are rare, aggressive tumors with a tendency toward recurrence following resection, and early metastasis. Although patients of younger or older age account for almost 30% of instances, peak incidences occur between the ages of 10 and 20. We, hereby, report the case of a 10-year-old girl who presented with a 3-month history of pain in her right hip that was unable to be relieved by non-steroidal anti-inflammatory medicine and physical therapy. On examination, bone marrow aspiration revealed that the infiltration of malignant small round blue cells was managed by anticancer therapy successfully.

Background Given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment, we studied mixed priming schedules incorporating an adenoviral-vectored vaccine (ChAdOx1 nCoV-19 [ChAd], AstraZeneca), two mRNA vaccines (BNT162b2 [BNT], Pfizer–BioNTech, and mRNA-1273 [m1273], Moderna) and a nanoparticle vaccine containing SARS-CoV-2 spike glycoprotein and Matrix-M adjuvant (NVX-CoV2373 [NVX], Novavax). Methods Com-COV2 is a single-blind, randomised, non-inferiority trial in which adults aged 50 years and older, previously immunised with a single dose of ChAd or BNT in the community, were randomly assigned (in random blocks of three and six) within these cohorts in a 1:1:1 ratio to receive a second dose intramuscularly (8–12 weeks after the first dose) with the homologous vaccine, m1273, or NVX. The primary endpoint was the geometric mean ratio (GMR) of serum SARS-CoV-2 anti-spike IgG concentrations measured by ELISA in heterologous versus homologous schedules at 28 days after the second dose, with a non-inferiority criterion of the GMR above 0·63 for the one-sided 98·75% CI. The primary analysis was on the per-protocol population, who were seronegative at baseline. Safety analyses were done for all participants who received a dose of study vaccine. The trial is registered with ISRCTN, number 27841311. Findings Between April 19 and May 14, 2021, 1072 participants were enrolled at a median of 9·4 weeks after receipt of a single dose of ChAd (n=540, 47% female) or BNT (n=532, 40% female). In ChAd-primed participants, geometric mean concentration (GMC) 28 days after a boost of SARS-CoV-2 anti-spike IgG in recipients of ChAd/m1273 (20 114 ELISA laboratory units [ELU]/mL [95% CI 18 160 to 22 279]) and ChAd/NVX (5597 ELU/mL [4756 to 6586]) was non-inferior to that of ChAd/ChAd recipients (1971 ELU/mL [1718 to 2262]) with a GMR of 10·2 (one-sided 98·75% CI 8·4 to ∞) for ChAd/m1273 and 2·8 (2·2 to ∞) for ChAd/NVX, compared with ChAd/ChAd. In BNT-primed participants, non-inferiority was shown for BNT/m1273 (GMC 22 978 ELU/mL [95% CI 20 597 to 25 636]) but not for BNT/NVX (8874 ELU/mL [7391 to 10 654]), compared with BNT/BNT (16 929 ELU/mL [15 025 to 19 075]) with a GMR of 1·3 (one-sided 98·75% CI 1·1 to ∞) for BNT/m1273 and 0·5 (0·4 to ∞) for BNT/NVX, compared with BNT/BNT; however, NVX still induced an 18-fold rise in GMC 28 days after vaccination. There were 15 serious adverse events, none considered related to immunisation. Interpretation Heterologous second dosing with m1273, but not NVX, increased transient systemic reactogenicity compared with homologous schedules. Multiple vaccines are appropriate to complete primary immunisation following priming with BNT or ChAd, facilitating rapid vaccine deployment globally and supporting recognition of such schedules for vaccine certification. Funding UK Vaccine Task Force, Coalition for Epidemic Preparedness Innovations (CEPI), and National Institute for Health Research. NVX vaccine was supplied for use in the trial by Novavax.

Obesity and diabetes prevalence are often referred to as the "twin epidemics" and are becoming a more widespread issue, particularly in developed countries. Advanced therapeutic strategies are therefore required. Tirzepatide, known as "twincretin", is a "firstclass" drug and the only agonist of glucagon-like peptide1 (GLP-1) and glucose-dependent peptide (GIP) receptors, which can significantly reduce blood sugar. levels and improved insulin sensitivity, as well as more than 20% reduction in body weight and improved lipid metabolism. This new antidiabetic drug is a synthetic peptide analog of human GIP hormone with a linkage to C20 fatty acid moiety that, through acylation process, can bind to albumin to deliver a single dose, by a single subcutaneous injection, once a week, consistent with its half-life of approximately five days. The "twincretin" heralded in an era of tremendously important and alluring dual therapy choices for diabetes and obesity, as well as advanced management of closely associated cardiometabolic settings, which are the primary global cause of illness, disability, and mortality. Here, we outline the salient features of tirzepatide's synthesis, structure, and action while also considering its benefits and drawbacks. Additionally, we briefly examine the progression of clinical research and the evolution of this type of medicinal medication

The current project aims to model and compare the performance of fake news detectors using machine learning algorithms to recognize fake news connected to political topics with high accuracy. The Decision Tree algorithm and the Random Forest algorithm are two algorithms. The methods were developed and evaluated on a dataset including 44,000 samples. Implemented each algorithm through programs and performed ten iterations with different scales of false feeds and factual feeds classification were identified. The G-power test is around 80% accurate. For detecting false political news, the Decision Tree algorithm had a mean accuracy of 99.6990, and the Random Forest approach had a mean accuracy of 98.6380, according to the trial results. The significance of accuracy is p=0.001, indicating the efficacy of the classifier. This research aims to use a novel strategy for contemporary Machine Learning Classifiers to predict fake political news. The comparison results reveal that the Decision Tree method outperforms the Random Forest technique.

Background: Priming COVID-19 vaccine schedules have been deployed at variable intervals globally, which may influence immune persistence and the relative importance of third-dose ‘booster’ programmes. Here, we report on the impact of 4- versus 12-week priming intervals on reactogenicity and the persistence of immune response up to 6 months following homologous and heterologous priming schedules using BNT162b2 (BNT, tozinameran, Comirnaty, Pfizer/BioNTech) and ChAdOx1 nCoV-19 (ChAd, Vaxzevria, AstraZeneca). Methods: Com-COV is a participant-blinded, randomised immunogenicity trial. Results are reported here for the ‘General’ cohort, in which adults aged over 50 years were randomised to four homologous and heterologous schedules using BNT and ChAd with 4- or 12-week priming intervals. Immunogenicity analyses were on the intention-to-treat population (ITT), without evidence of COVID-19 infection at baseline or for the trial duration, with the purpose of describing the effect of priming interval on humoral and cellular immune response at peak and later timepoints, in addition to the effects on reactogenicity and safety Findings: Between 11th–26th Feb 2021, 730 participants were randomised in the general cohort, with 77-89 per arm in the ITT analysis. At 28-days and 6-months post-second dose, the geometric mean concentration (GMC) of anti-SARS-CoV-2 spike IgG was significantly higher in 12- versus 4-week interval arms for homologous schedules. In heterologous arms, there was only a significant difference between intervals for the BNT/ChAd arm at 28-days. Pseudotyped virus neutralisation titres were significantly higher in all 12-week versus 4-week schedules, 28-days post-second dose, with geometric mean ratios 1.4 (95%CI: 1.1-1.8, BNT/BNT), 1.5 (95%CI: 1.2-1.9, ChAd/BNT), 1.6 (95%CI 1.3-2.1, BNT/ChAd) and2.4 (95%CI: 1.7-3.2, ChAd/ChAd). At 6 months post-second dose, anti-spike IgG GMCs fell to 0.17-0.24 of the 28-day post-second dose value across all eight study arms, with only BNT/BNT displaying a slightly slower decay for the 12-week versus 4-week schedule in the adjusted analysis. The rank order of schedules by humoral response was unaffected by interval with BNT/BNT remaining the most immunogenic by antibody response. T-cell responses were reduced in all 12-week priming intervals versus their 4-week counterparts. 12-week schedules for BNT/BNT and ChAd/BNT schedules were up to 80% less reactogenic than 4-week schedules. Interpretation: These data support flexibility in priming interval in all studied COVID-19 vaccine schedules. Longer priming intervals may result in lower reactogenicity in schedules with BNT as a second-dose and higher humoral immunogenicity in homologous schedules, but overall lower T-cell responses across all schedules. Future vaccines employing these novel platforms may benefit from prolonged-interval schedules. ISRCTN:69254139, EudraCT:2020-005085-33.

AZD1222 (ChAdOx1 nCoV-19), a replication-deficient simian adenovirus-vectored vaccine, has demonstrated safety, efficacy, and immunogenicity against coronavirus disease 2019 (COVID-19) in clinical trials and real-world studies. We characterized CD4+ and CD8+ T cell responses induced by AZD1222 vaccination in peripheral blood mononuclear cells (PBMCs) from 296 unique vaccine recipients aged 18 to 85 years who enrolled in the phase 2/3 COV002 trial. Total spike protein-specific CD4+ T cell helper type 1 (Th1) and CD8+ T cell responses were increased in AZD1222-vaccinated adults of all ages following two doses of AZD1222. CD4+ Th2 responses following AZD1222 vaccination were not detected. Furthermore, AZD1222-specific Th1 and CD8+ T cells both displayed a high degree of polyfunctionality in all adult age groups. T cell receptor (TCR) β sequences from vaccinated participants mapped against TCR sequences known to react to SARS-CoV-2 revealed substantial breadth and depth across the SARS-CoV-2 spike protein for both AZD1222-induced CD4+ and CD8+ T cell responses. Overall, AZD1222 vaccination induced a polyfunctional Th1-dominated T cell response, with broad CD4+ and CD8+ T cell coverage across the SARS-CoV-2 spike protein.

E-health is a field which as seen tremendous growth in the recent times especially after the covid-19 outbreak. E-health offers the potential to provide patients with high-quality care at a reasonable cost in the ease of their own homes. E-health has a wide range of application that includes rehabilitation, cognitive disorder, behavioural therapy, defence application and many more. E-health as a technology is changing tremendously and always been evolving to meet the demands of the current practices. But still, it has certain challenges in implementing such as ethical issues, patient contest etc. Artificial intelligence framework capable of using non-consultancy, reinforcement learning, and all three. Controlling the processes within the m-Health application, choosing the best processes that can be used to alter the user's existing conditions, or selecting the best diagnosis-solution from an array of choices are all supported by intelligent optimization algorithms that can offer faster feedback.

The global supply of COVID-19 vaccines remains limited. An understanding of the immune response that is predictive of protection could facilitate rapid licensure of new vaccines. Data from a randomized efficacy trial of the ChAdOx1 nCoV-19 (AZD1222) vaccine in the United Kingdom was analyzed to determine the antibody levels associated with protection against SARS-CoV-2. Binding and neutralizing antibodies at 28 days after the second dose were measured in infected and noninfected vaccine recipients. Higher levels of all immune markers were correlated with a reduced risk of symptomatic infection. A vaccine efficacy of 80% against symptomatic infection with majority Alpha (B.1.1.7) variant of SARS-CoV-2 was achieved with 264 (95% CI: 108, 806) binding antibody units (BAU)/ml: and 506 (95% CI: 135, not computed (beyond data range) (NC)) BAU/ml for anti-spike and anti-RBD antibodies, and 26 (95% CI: NC, NC) international unit (IU)/ml and 247 (95% CI: 101, NC) normalized neutralization titers (NF50) for pseudovirus and live-virus neutralization, respectively. Immune markers were not correlated with asymptomatic infections at the 5% significance level. These data can be used to bridge to new populations using validated assays, and allow extrapolation of efficacy estimates to new COVID-19 vaccines., Defined levels of SARS-CoV-2-specific binding and neutralizing antibodies elicited by the COVID-19 vaccine ChAdOx1 nCoV-19 are identified as correlates of protection against symptomatic infection.

Introduction: The Vision 2015 of Medical Council of India states that the Indian medical graduate (IMG) should have the necessary competencies (Knowledge, Skills and Attitude) to assume his or her role as a health care provider to the people of India and the World. Early Clinical Exposure (ECE) is one of the measures taken by MCI to enact its vision. Objectives: This study was aimed to evaluate the effectiveness of ECE in learning clinical examination skills among preclinical students and to explore the perspectives of ECE among the students and faculty. Materials and Methods: Present study was conducted in the department of Physiology, Govt. Thiruvarur Medical College, Thiruvarur on 99 medical students. After obtaining informed, written consent pretest questionnaire was given to the study participants. After obtaining informed, written consent pre-test questionnaire was given to the study participants. After that students were allocated into Group 1 (n=49) and Group 2 (n=50) by simple random technique by lottery method. Group 1 students were trained on clinical examination of anemia in medicine ward (Early Clinical Exposure) and Group 2 students were trained on clinical examination of anemia in clinical physiology laboratory (Control). At the end of the session both groups were assessed by Post-test questionnaire and Objective Structured Clinical Examination (OSCE). Crossing over of the batches was done in the next session for training of clinical examination of jaundice. Feedback was obtained from the students (n=99) and faculty members involved in this (n=7). Results: There was a statistically significant difference present between the post test scores of Group 1 and Group 2 in anemia and jaundice (p Conclusion: Results of the present study justify the need of Early Clinical Exposure to teach clinical examination skills to first year medical students when compared to the traditional teaching method. Keywords: Early clinical exposure, First year medical stu